Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis.
- Author:
Yo Han CHO
1
;
So Young YOON
;
Soo Nyung KIM
Author Information
- Publication Type:Meta-Analysis ; Randomized Controlled Trial ; Original Article
- Keywords: Stomach neoplasms; Chemotherapy; Second-line; Irinotecan; Monotherapy; Combination drug therapy; Meta-analysis; Survival
- MeSH: Cisplatin; Disease-Free Survival; Drug Therapy*; Drug Therapy, Combination; Humans; Stomach Neoplasms*
- From:Cancer Research and Treatment 2017;49(1):255-262
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: A meta-analysis was conducted to examine the question of whether combination regimens are more effective than monotherapy as a second-line chemotherapy in advanced gastric cancer. MATERIALS AND METHODS: The MEDLINE and the EMBASE databases and the Cochrane Central Register for Controlled Trials were searched using appropriate keywords. Only randomized controlled trials were eligible. RESULTS: Taxane-based study is rare; thus, four irinotecan-based studies were finally included in the meta-analysis. Out of 661 patients, 331 patients were assigned to combination therapy and 330 to monotherapy. Cisplatin or fluoropyrimidine (S-1 or 5-fluorouracil) was used as a combination partner to irinotecan. The pooled hazard ratio (HR) for overall survival (OS) and for progression-free survival (PFS) was 0.938 (95% confidence interval [CI], 0.796 to 1.104; p=0.442) and 0.815 (95% CI, 0.693 to 0.958; p=0.013). In subgroup analysis according to previous exposure to a partner agent, the PFS benefit of combination was observed only in the partially exposed group (HR, 0.784; 95% CI, 0.628 to 0.980; p=0.032). CONCLUSION: Second-line irinotecan-based combination was not associated with increased OS, but with PFS benefit, which seemed particularly significant for patients receiving combination with a new agent.
